Foghorn Therapeutics (FHTX) Net Cash Flow Growth (1y) (2020 - 2026)
Foghorn Therapeutics (FHTX) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Foghorn Therapeutics |
282.33 Mn |
193.42 Mn |
- |
21.81% |
| Date | Value |
|---|
| Mar 31, 2026 |
21.81% |
| Dec 31, 2025 |
-280.31% |
| Sep 30, 2025 |
120.63% |
| Jun 30, 2025 |
-78.07% |
| Mar 31, 2025 |
614.50% |
| Dec 31, 2024 |
-122.17% |
| Sep 30, 2024 |
-744.84% |
| Jun 30, 2024 |
745.28% |
| Mar 31, 2024 |
31.15% |
| Dec 31, 2023 |
128.32% |
| Sep 30, 2023 |
-52.26% |
| Jun 30, 2023 |
104.63% |
| Mar 31, 2023 |
-101.40% |
| Dec 31, 2022 |
-181.80% |
| Sep 30, 2022 |
139.21% |
| Jun 30, 2022 |
-359.62% |
| Mar 31, 2022 |
527.04% |
| Dec 31, 2021 |
145.52% |
| Sep 30, 2021 |
-276.91% |
| Jun 30, 2021 |
77.29% |
